A comparison of low versus high dose pamidronate in cancer-associated hypercalcaemia.

No abstract is available for this paper.

• Publication year

  1991

• Venue

  Bone and Mineral

• Publication date

  1991-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/0169-6009(91)90130-RPMID 1773137
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Two-Site Immunoradiometric Assay for Pth(1–84) Using N and C Terminal Specific Monoclonal Antibodies

  1991cited by this paper
• Dose of bisphosphonate for hypercalcaemia of malignancy.

  1990cited by this paper
• Chronic high-dose pamidronate in refractory malignant hypercalcaemia

  1990cited by this paper
• Chronic high-dose pamidronate in refractory malignant hypercalcaemia.

  1990cited by this paper
• Comparison of different dose regimes of aminohydroxypropylidene-1,1-bisphosphonate (APD) in hypercalcaemia of malignancy.

  1989cited by this paper
• Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia.

  1989cited by this paper
• Renal phosphate threshold and response to pamidronate in humoral hypercalcaemia of malignancy.

  1989cited by this paper
• Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow.

  1989cited by this paper
• Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP.

  1988cited by this paper
• Clinical experience with aminohydroxypropylidene bisphosphonate (APD) in the management of cancer-associated hypercalcaemia.

  1988cited by this paper
• Dose/response study of aminohydroxypropylidene bisphosphonate in tumor-associated hypercalcemia.

  1987cited by this paper
• Arginine infusion blocks the action of parathyroid hormone but not arginine vasopressin on the renal tubule in man.

  1986cited by this paper
• Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix.

  1986cited by this paper
• Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix.

  1986cited by this paper
• Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia.

  1985cited by this paper
• Hypercalcaemia and metastatic bone disease: is there a causal link?

  1982cited by this paper
• Efficacy of amino-hydroxypropylidene bisphosphonate in hypercalcemia: Observations on regulation of serum calcium

  1982cited by this paper
• Predictive Value of Derived Calcium Figures Based on the Measurement of Ionised Calcium

  1981cited by this paper
• Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and nonhumoral groups.

  1980cited by this paper
• APD in Paget's disease of bone. Role of the mononuclear phagocyte system?

  1980cited by this paper
• NOMOGRAM FOR DERIVATION OF RENAL THRESHOLD PHOSPHATE CONCENTRATION

  1975cited by this paper

• A Review of Current Clinical Concepts in the Pathophysiology, Etiology, Diagnosis, and Management of Hypercalcemia

  2022cites this paper
• A systematic review of the role of bisphosphonates in metastatic disease.

  2004cites this paper
• Systematic review of bisphosphonates for hypercalcaemia of malignancy

  2004cites this paper
• Current Management Strategies for Hypercalcemia

  2003cites this paper
• Ectopic hormone syndromes

  2002cites this paper
• Comparative Tolerability of Drug Therapies for Hypercalcaemia of Malignancy

  1999cites this paper
• Chapter 13 – Primary Hyperparathyroidism

  1998cites this paper
• Hyperparathyroidism and other hypercalcemic disorders.

  1996cites this paper
• An audit of the management of malignant hypercalcaemia.

  1996cites this paper
• Gas chromatographic analysis of 3-amino-1-hydroxypropylidene-1,1-bisphosphonate and related bisphosphonate as their N-isobutoxycarbonyl methyl ester derivatives

  1996cites this paper
• Pamidronate for cancer-associated hypercalcemia.

  1995cites this paper
• Selective and sensitive determination of pamidronate in human plasma and urine by gas chromatography with flame photometric detection.

  1995cites this paper
• Pathogenesis and management of cancer associated hypercalcaemia.

  1994cites this paper
• Pamidronate treatment in patients with tumor-associated hypercalcemia: pharmacological effects and pharmacokinetics.

  1994cites this paper
• Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type.

  1994cites this paper
• Usefulness of biochemical markers of bone turnover in rats after clodronate administration.

  1993cites this paper
• Pathophysiology and management of severe hypercalcemia.

  1993cites this paper
• Drugs Used in the Treatment of Metabolic Bone Disease

  1993cites this paper
• Medical management of hypercalcaemia.

  1992cites this paper
• Factors predicting the acute effect of pamidronate on serum calcium in hypercalcemia of malignancy

  1992cites this paper
• Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease: an open pilot study.

  1992cites this paper